Clinical Trial Update: A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 study of baricitinib plus topical corticosteroids in adults with moderate-to-severe atopic dermatitis completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2020-08-11